Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab versus etanercept in high-need moderate to severe chronic plaque psoriasis
NL-OMON35488Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in psoriasis comparing Etanercept first with Infliximab first (2 arms). Primary endpoints: Clinical efficacy at weeks 12 and 24, Health-related quality of life and 3 more. Planned start Mar 2009; status: not yet recruiting.
02
Drugs
infliximabetanercept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON35488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35488.